Search

Your search keyword '"Boch, Tobias"' showing total 208 results

Search Constraints

Start Over You searched for: Author "Boch, Tobias" Remove constraint Author: "Boch, Tobias"
208 results on '"Boch, Tobias"'

Search Results

1. Treatment with the apoptosis inhibitor Asunercept reduces clone sizes in patients with lower risk Myelodysplastic Neoplasms

4. Abstract: Multistage Registration of CT and Biopsy CT Images of Lung Tumors

8. Abstract: Multistage Registration of CT and Biopsy CT Images of Lung Tumors

9. Performance of the Bronchoalveolar Lavage Fluid Aspergillus Galactomannan Lateral Flow Assay With Cube Reader for Diagnosis of Invasive Pulmonary Aspergillosis: A Multicenter Cohort Study

14. Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes

15. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.

16. Single-cell proteo-genomic reference maps of the hematopoietic system enable the purification and massive profiling of precisely defined cell states

17. Galactomannan testing and Aspergillus PCR in same-day bronchoalveolar lavage and blood samples for diagnosis of invasive aspergillosis

18. ONCO-FETAL REPROGRAMMING DRIVES HIGH-RISK JUVENILE MYELOMONOCYTIC LEUKEMIA, WHICH CAN BE TARGETED BY ANTI-CD52 TREATMENT

19. Oncogenic RAS-Pathway Activation Drives Oncofetal Reprogramming and Creates Therapeutic Vulnerabilities in Juvenile Myelomonocytic Leukemia

20. Identification of leukemic and pre-leukemic stem cells by clonal tracking from single-cell transcriptomics

21. Myelodysplastische Syndrome

22. S206: ONCO-FETAL REPROGRAMMING DRIVES HIGH-RISK JUVENILE MYELOMONOCYTIC LEUKEMIA, WHICH CAN BE TARGETED BY ANTI-CD52 TREATMENT

24. Multiple myeloma long-term survivors display sustained immune alterations decades after first line therapy

25. OC 34 - ONCO-FETAL REPROGRAMMING DRIVES HIGH-RISK JUVENILE MYELOMONOCYTIC LEUKEMIA, WHICH CAN BE TARGETED BY ANTI-CD52 TREATMENT

26. Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure

28. Exploring Genetic and Non-Genetic Changes Driving Tumor Evolution in CK-AML at Single-Cell Resolution

29. Direct Comparison of NSG and NBSGW Mice for MDS Patient-Derived Xenograft Models

30. Multi-Omics Profiling of JMML HSPCs Reveals Onco-Fetal Reprogramming and Identifies Novel Prognostic Biomarkers and Therapeutic Targets in High-Risk JMML

32. Socio-economic burden of disease: survivorship costs for soft tissue sarcoma

34. Myelodysplastische Syndrome

36. Antigen presentation safeguards the integrity of the hematopoietic stem cell pool

38. Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery

43. 3019 – SINGLE-CELL PROTEO-GENOMIC REFERENCE MAPS OF THE HEMATOPOIETIC SYSTEM ENABLE THE PURIFICATION AND MASSIVE PROFILING OF PRECISELY DEFINED CELL STATES

44. Comparison of extraction methods for intracellular metabolomics

47. Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes

48. Single-cell proteo-genomic reference maps of the hematopoietic system enable the purification and massive profiling of precisely defined cell states

49. High erythroferrone expression in CD71+ erythroid progenitors predicts superior survival in myelodysplastic syndromes

Catalog

Books, media, physical & digital resources